Clinical Trials on Giant Cell Tumors in New Zealand

Total 7643 results

Astellas Pharma Inc
OSI Pharmaceuticals; Cell Pathways

Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Malignant Melanoma

United States
Memorial Sloan Kettering Cancer Center
Yale University; University of New Mexico

Completed

Differential Risks for Melanoma: p16 and DNA Repair

Melanoma | Skin Melanoma

United States
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center

Completed

Study of gp75 Vaccine in Patients With Stage III and IV Melanoma

Malignant Melanoma

United States
Massachusetts General Hospital
M.D. Anderson Cancer Center; Memorial Sloan Kettering Cancer Center; Dana-Farber...

Completed

Detecting EGFR T790M Mutations From Circulating Tumor Cells

Non Small Cell Lung Cancer

United States
Novartis Pharmaceuticals

Completed

Retrospective Assessment of AE-Related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

United States
Novartis Pharmaceuticals

Completed

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Melanoma

United States
NYU Langone Health
Celldex Therapeutics

Terminated

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

Melanoma

United States
Columbia University
Merck Sharp & Dohme LLC

Terminated

MRI and PET to Assess Pembrolizumab Response (MPAK)

Malignant Melanoma, Metastatic

United States
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Chemotherapy, Radiation Therapy, Immunotherapy, and Bone Marrow Transplantation in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Rebeccamycin Analog in Treating Children With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Bristol-Myers Squibb
Medarex; Ono Pharma USA Inc

Completed

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Melanoma Institute Australia
Novartis

Recruiting

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

Melanoma

Australia
Ludwig Institute for Cancer Research
Bristol-Myers Squibb; Conquer Cancer Foundation

Completed

Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma

Melanoma

United States
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Ethanol-Lock Treatment in Preventing Central Venous Catheter Infections in Patients With High-Risk Neuroblastoma

Neuroblastoma

United States
Dartmouth-Hitchcock Medical Center

Terminated

Metronomic Therapy in Patients With Metastatic Melanoma

Metastatic Melanoma

United States
Yale University
Novartis

Terminated

A Study of Everolimus in Combination With Imatinib in Metastatic Melanoma

Metastatic Melanoma

United States
Clarity Pharmaceuticals Ltd

Active, not recruiting

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Neuroendocrine Tumors

Australia
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors

Islet Cell Tumor | Gastrointestinal Carcinoid Tumor | Neoplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls

Germ Cell Cancer

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and GM-CSF in Treating Young Patients With High-Risk, Refractory or Relapsed Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Monoclonal Antibody Therapy Plus Sargramostin in Treating Patients With Advanced Neuroblastoma

Neuroblastoma

United States
QBiotics Group Limited
Merck Sharp & Dohme LLC

Terminated

A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma

Melanoma

Australia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Malignant Germ Cell Tumors

Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor

Canada, United States, Australia, Puerto Rico
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

Neuroblastoma | High-risk Neuroblastoma | Metastatic Neuroblastoma

United States
Melanoma Institute Australia
Merck Sharp & Dohme LLC

Not yet recruiting

Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM)

Mucosal Melanoma

Australia
Memorial Sloan Kettering Cancer Center
Pfizer

Recruiting

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

Mucosal Melanoma

United States
Yale University

Terminated

A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

Metastatic Melanoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Health Behaviors, Surveillance, Psychosocial Factors, and Family Concerns

Melanoma | Survivors | Psychological Factors

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Neuroblastoma | Ganglioneuroblastoma, Nodular

United States, Australia, Canada, New Zealand
Hutchmed

No longer available

Expanded Access Program of Surufatinib

Neuroendocrine Tumors

United States
Icahn School of Medicine at Mount Sinai
Bristol-Myers Squibb

Terminated

CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Determine Toxicity and Antibody Responses With a KLH Conjugated Bivalent Vaccine Containing GD2 Lactone, GD3 Lactone With Immunological Adjuvant QS-DG or OPT-821 in Patients With Disease Free AJCC Stage III or IV Cutaneous Melanoma

Melanoma

United States
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital; Weill Medical College of Cornell University

Active, not recruiting

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Melanoma

United States
Adil Daud
National Comprehensive Cancer Network

Completed

Trametinib With GSK2141795 in BRAF Wild-type Melanoma

Melanoma

United States
Provectus Pharmaceuticals

Completed

Intralesional PV-10 Chemoablation of Metastatic Melanoma

Melanoma

Australia
Memorial Sloan Kettering Cancer Center

Completed

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Neuroblastoma | Bone Marrow, Sympathetic Nervous System

United States
Hackensack Meridian Health
National Cancer Institute (NCI)

Withdrawn

High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma

Melanoma (Skin)

United States
National Cancer Institute (NCI)

Completed

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

Adult Anaplastic Astrocytoma | Adult Anaplastic Oligodendroglioma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Recurrent Adult Brain Neoplasm

United States
Novartis Pharmaceuticals

Terminated

Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib

Metastatic Melanoma

United States
Eli Lilly and Company

Completed

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

Malignant Melanoma

United States
QBiotics Group Limited

Terminated

A Trial of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c Melanoma

Melanoma

Australia
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Melanoma | Sarcoma | Breast Cancer | Solid Tumor | Prostate Cancer | Bladder Cancer | Head and Neck Squamous Cell Carcinoma | Cutaneous T-Cell Lymphoma | Renal Cancer | Merkel Cell Carcinoma | Testicular Cancer

United States
Memorial Sloan Kettering Cancer Center

Completed

Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma

Melanoma

United States
NYU Langone Health
Bristol-Myers Squibb; Daiichi Sankyo, Inc.

Completed

Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma

Melanoma

United States
Ichor Medical Systems Incorporated
Memorial Sloan Kettering Cancer Center

Completed

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

Intraocular Melanoma | Melanoma (Skin)

United States

Clinical Trials on Giant Cell Tumors in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations